Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...
Recursion Pharmaceuticals' stock had dropped over 50% since February 2024 due to underwhelming clinical results and significant shareholder dilution from a secondary offering and merger. Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback